-
公开(公告)号：EP3458060A1
公开(公告)日：2019-03-27
申请号：EP17800027.9
申请日：2017-05-16
申请人： Foster, Howell
发明人： Foster, Howell
IPC分类号： A61K31/475 , A61K31/519 , A61K31/4985 , A61P15/00 , A61K31/505 , A61K31/495 , A61K31/343
-
22.发明授权
公开(公告)号：EP2922529B1
公开(公告)日：2019-03-13
申请号：EP13814676.6
申请日：2013-11-20
IPC分类号： A61K9/127 , A61K31/475
-
公开(公告)号：EP3386499A1
公开(公告)日：2018-10-17
申请号：EP16874055.3
申请日：2016-12-12
IPC分类号： A61K31/337 , A61K31/427 , A61K31/475
摘要： Angiotensin (1-7) analogs are provided. The analogs contain one or more substitutions with non-natural amino acid cis-3-(aminomethyl)cyclobutanecarboxylic acid (ACCA). Also provided are methods of making such analogs and methods for using such analogs as therapeutic compositions to treat or prevent various diseases or conditions.
-
公开(公告)号：EP3325100A1
公开(公告)日：2018-05-30
申请号：EP16828326.5
申请日：2016-07-15
IPC分类号： A61P35/00 , A61K31/437 , A61K31/475 , A61K39/395
CPC分类号： A61K31/713 , A61K31/4439 , A61K31/506 , A61K31/7105 , A61K31/711 , A61K45/06 , A61P35/00 , A61K2300/00
摘要： The present invention relates to methods and compositions for inhibiting growth and proliferation of cancer cells resistant to PI3K inhibition using a combination of PDK1, SGK1 and PI3K inhibitors. The present invention is also directed to methods of treating cancer in a subject exhibiting cancer cells resistant to PI3K inhibition, comprising administering inhibitors of PI3K in combination with inhibitors of PDK1 and/or SGK1 to the subject.
-
25.发明公开
公开(公告)号：EP3324968A2
公开(公告)日：2018-05-30
申请号：EP16827318.3
申请日：2016-07-21
发明人： KWAN, Min-fun, Rudolf , KRAMER, E., Douglas , FETTERLY, Geralk, J. , HUNG, Cheung-tak , JACKSON, Christopher Glyn Charles, Alexander , GLUE, Paul, William
IPC分类号： A61K31/475 , A61K31/337 , A61P35/00
CPC分类号： A61K31/4725 , A61K31/337 , A61K2300/00 , A61P35/02
摘要： The application pertains to pharmaceutical combinations of orally administered paclitaxel and a P-gp inhibitor. The pharmaceutical combinations are suitable for the treatment of cancer in a subject and for reducing or preventing toxicity, hypersensitivity-type infusion reactions, and other negative outcomes resulting from or associated with intravenously administered paclitaxel (e.g., Taxol® or paclitaxel formulated with Cremophor®) therapy in a subject suffering from cancer.
-
26.发明授权FUSED ACRIDINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION, PREPARATION METHOD AND USE THEREOF 有权融合吖啶衍生物和药物组合物，其制备方法及其用途
公开(公告)号：EP3098222B1
公开(公告)日：2018-04-18
申请号：EP15755083.1
申请日：2015-02-15
申请人： Peking University
发明人： MENG, Xiangbao , LI, Zhongjun , LIU, Shan , YU, Siwang , QUE, Linling
IPC分类号： C07D471/06 , A61K31/475 , A61K31/5377 , A61P35/00
CPC分类号： C07D471/06
摘要： Provided is a fused acridine derivative as formula (I), which has good antitumor activity. In addition, also provided are a process for preparing the derivative, a pharmaceutical composition containing the derivative, and the use thereof.
-
公开(公告)号：EP3185884A4
公开(公告)日：2018-04-11
申请号：EP15836791
申请日：2015-08-27
申请人： ONCOMED PHARM INC
发明人： GURNEY AUSTIN , YEN WAN CHING
IPC分类号： A61K38/17 , A61K31/337 , A61K31/475 , A61K39/00 , A61K39/395 , A61P35/00 , C07K16/28 , C07K16/30
CPC分类号： C07K16/30 , A61K31/337 , A61K31/475 , A61K38/177 , A61K39/395 , A61K2039/505 , A61K2039/545 , A61P35/00 , C07K16/2863 , C07K2317/56 , C07K2317/565 , C07K2317/73 , A61K2300/00
摘要： The present invention provides methods comprising combination therapy for treating cancer. Wnt pathway inhibitors in combination with mitotic inhibitors administered in a staggered or sequential dosing manner for the treatment of cancer and other diseases.
-
公开(公告)号：EP3148547A4
公开(公告)日：2018-01-10
申请号：EP15802818
申请日：2015-06-02
申请人： HUANG CHI-YING
IPC分类号： A61K31/5415 , A61K31/282 , A61K31/337 , A61K31/4745 , A61K31/475 , A61K31/496 , A61K31/513 , A61K31/517 , A61K31/519 , A61K31/5377 , A61K31/555 , A61K31/7068 , A61K33/24 , A61K45/06 , A61P35/00 , A61P35/04
CPC分类号： A61K31/5415 , A61K31/282 , A61K31/337 , A61K31/4745 , A61K31/475 , A61K31/513 , A61K31/517 , A61K31/519 , A61K31/5377 , A61K31/555 , A61K31/7068 , A61K33/24 , A61K45/06 , A61K2300/00
摘要： The present invention relates to a method for treating a subject with a cancer resistant to a chemotherapeutic drug comprising administering to said subject a therapeutically effective amount of prochlorperazine or its analog or metabolite, or a pharmaceutically acceptable salt thereof, in combination of the chemotherapeutic drug. The present invention also relates to a method for preventing cancer metastasis with the combination of prochlorperazine in combination of a chemotherapeutic drug.
-
公开(公告)号：EP3113776A4
公开(公告)日：2017-11-15
申请号：EP15759326
申请日：2015-03-06
发明人： LONGO VALTER D , DI BIASE STEFANO
IPC分类号： A61K31/4745 , A61K31/436 , A61K31/475 , A61K31/704 , A61P35/00
CPC分类号： A61K31/4745 , A61K31/436 , A61K31/475 , A61K31/704 , A61K2300/00
-
公开(公告)号：EP3169366A1
公开(公告)日：2017-05-24
申请号：EP15744790.5
申请日：2015-07-10
发明人： DI PAOLO, Julie , CLARKE, Astrid
IPC分类号： A61K45/06 , A61K31/475 , A61K31/4985 , A61P35/00
CPC分类号： A61K31/5377 , A61K31/475 , A61K31/4985 , A61K45/06 , A61K2300/00
摘要： Disclosed are methods for treating a cancer in a subject (e.g., a human) in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of formula I: or a pharmaceutically acceptable salt thereof; in combination with a vinca-alkaloid, or a pharmaceutically acceptable salt thereof. The subject may be very high risk or high risk for the cancer and may not respond to either agent administered as a sole therapy. The subject who has the cancer may also be refractory to at least one chemotherapy treatment, or is in relapse after treatment with chemotherapy, or both. The cancer may be a hematologic malignancy, such as leukemia or lymphoma, or a solid tumor cancer, such as pancreatic, lung and colon cancer.
摘要翻译： 公开了用于治疗有需要的受试者（例如人）的癌症的方法，其包括向受试者施用治疗有效量的式I化合物或其药学上可接受的盐; 与长春花生物碱或其药学上可接受的盐组合。 受试者可能是非常高风险或高风险的癌症，并且可能对作为唯一疗法施用的任一药剂都不响应。 患有癌症的受试者对于至少一种化学疗法治疗也是难治性的，或者在用化学疗法治疗后复发或两者兼有。 癌症可以是血液恶性肿瘤，如白血病或淋巴瘤，或实体肿瘤癌症，如胰腺癌，肺癌和结肠癌。
-
-
-
-
-
-
-
-
-
搜索结果
776 条记录 (耗时 0.024 秒)
